Blood

Journal

Publication Venue For

  • Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.  136:936-945. 2020
  • One-two punch of cytokine storm syndrome.  136:645-646. 2020
  • A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. 2020
  • An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.  135:2337-2353. 2020
  • How I treat unexplained arterial thrombosis. 2020
  • Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.  135:2094-2105. 2020
  • Erdheim-Chester disease: Consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.  135:1929-1945. 2020
  • Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study.  135:1833-1846. 2020
  • Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.  135:463-471. 2020
  • Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission.  134:48. 2019
  • Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.  134:33. 2019
  • Inherited genetic susceptibility to acute lymphoblastic leukemia in down syndrome.  134:1227-1237. 2019
  • Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.  134:1095-1105. 2019
  • PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD1 acute myeloid leukemia.  134:548-560. 2019
  • A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403.  133:1548-1559. 2019
  • Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.  133:1607-1610. 2019
  • Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma.  133:1130-1139. 2019
  • SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.  132:1737-1749. 2018
  • A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.  132:1125-1133. 2018
  • AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation.  132:1180-1192. 2018
  • Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the children’s oncology group.  132:815-824. 2018
  • Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.  131:2782-2788. 2018
  • Late mortality after autologous blood or marrow transplantation in childhood: A Blood or Marrow Transplant Survivor Study-2 report.  131:2720-2729. 2018
  • Mechanisms of resistance to ezh2 inhibitors in diffuse large b-cell lymphomas.  131:2125-2137. 2018
  • hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival.  131:1532-1544. 2018
  • Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.  131:1415-1424. 2018
  • CD38 pretargeted RIT of B-cell tumors.  131:589-590. 2018
  • A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.  131:387-396. 2018
  • Histiocytic sarcoma: A population-based analysis of incidence, demographic disparities, and long-term outcomes.  131:265-268. 2018
  • Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: A PIDTC natural history study.  130:2718-2727. 2017
  • Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study.  130:2527-2536. 2017
  • How I monitor long-term and late effects after blood or marrow transplantation.  130:1302-1314. 2017
  • PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: High response rate but frequent GVHD.  130:221-228. 2017
  • Targetable kinase gene fusions in high-risk B-ALL: A study from the Children's Oncology Group.  129:3352-3361. 2017
  • Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: A Children’s Oncology Group study.  129:1919-1926. 2017
  • Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.  129:1763-1767. 2017
  • Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation.  129:1184-1196. 2017
  • Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.  129:1008-1020. 2017
  • Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function.  129:799-801. 2017
  • Severe anemia early in life as a risk factor for sickle-cell kidney disease.  129:385-387. 2017
  • Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells.  128:2671-2682. 2016
  • Modeling altered T-cell development with induced pluripotent stem cells from patients with RAG1-dependent immune deficiencies.  128:783-793. 2016
  • Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: A potential link of inflammation to TTP.  128:110-119. 2016
  • Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.  127:464-472. 2016
  • Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP.  blood-2015. 2016
  • Predictors for in-Hospital Mortality in Patients with Autoimmune Thrombotic Thrombocytopenia Purpura (TTP): A Single Center Experience 2016
  • Incidence of breast cancer among female survivors of Hodgkin lymphoma: A US-population-based trend analysis from 1973 to 2011.  126:1861-1863. 2015
  • Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children's Oncology Group study AALL0232.  126:964-971. 2015
  • Race influences warfarin dose changes associated with genetic factors.  126:539-545. 2015
  • Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.  125:4103-4113. 2015
  • Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development.  125:2678-2688. 2015
  • ADAMTS13, lucky to have a hydrophobic pocket.  125:1852-1853. 2015
  • MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors.  125:1302-1313. 2015
  • Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.  125:591-599. 2015
  • Lymphoid neoplasia: A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.  125:680-686. 2015
  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.  125:1367-1376. 2015
  • Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: A matched cohort study.  125:3359-3360. 2015
  • Myeloma cell-derived Runx2 promotes myeloma progression in bone.  125:3598-3608. 2015
  • Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models.  125:3326-3334. 2015
  • The tumor virus landscape of AIDS-related lymphomas.  125:e14-e22. 2015
  • Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia.  124:3833-3834. 2014
  • Exploiting the kinetic interplay between GPIbα-VWF binding interfaces to regulate hemostasis and thrombosis.  124:3799-3807. 2014
  • Leukemia cells make ruthless competitors.  124:2900-2901. 2014
  • 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: A Children's Oncology Group study.  124:2345-2353. 2014
  • The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells.  124:2391-2399. 2014
  • Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.  124:2298-2305. 2014
  • The DPY30 subunit in SET1/MLL complexes regulates the proliferation and differentiation of hematopoietic progenitor cells.  124:2025-2033. 2014
  • Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.  124:1915-1925. 2014
  • JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.  124:1492-1501. 2014
  • Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.  124:287-295. 2014
  • Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.  123:3895-3905. 2014
  • Posttranscriptional regulation of c-Myc expression in adult murine HSCs during homeostasis and interferon-α-induced stress response.  123:3909-3913. 2014
  • Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.  123:2826-2837. 2014
  • DNase, ADAMTS13, and iPAD4: Good for the heart.  123:10-11. 2014
  • Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.  123:15-25. 2014
  • Disseminated fusariosis during acute myelogenous leukemia induction treatment.  123:3379. 2014
  • Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.  122:3863-3870. 2013
  • Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: Impact of chronic graft-Versus-Host disease and total body irradiation.  122:3973-3981. 2013
  • A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.  122:3432-3439. 2013
  • T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.  122:3138-3148. 2013
  • A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.  121:4854-4860. 2013
  • Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: An analysis of 3691 cases.  121:4861-4866. 2013
  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts.  121:4439-4442. 2013
  • C/EBPΑ is required for development of dendritic cell progenitors.  121:4073-4081. 2013
  • Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.  121:4175-4183. 2013
  • AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura.  121:3825-3829. 2013
  • Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential..  121:3714-3717. 2013
  • MiR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.  121:2875-2881. 2013
  • Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.  121:1824-1838. 2013
  • In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells.  121:1255-1264. 2013
  • TLR9-mediated siRNA delivery for Targeting of normal and malignant human hematopoietic cells in vivo.  121:1304-1315. 2013
  • Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study.  121:537-545. 2013
  • Inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.  121:385-391. 2013
  • Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation.  122:3335-3339. 2013
  • Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.  121:2689-2703. 2013
  • The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.  122:1900-1913. 2013
  • The role of chromatin modifiers in normal and malignant hematopoiesis.  121:3076-3084. 2013
  • Cardiovascular risk factors in hematopoietic cell transplantation survivors: Role in development of subsequent cardiovascular disease.  120:4505-4512. 2012
  • Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.  120:4134-4142. 2012
  • Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.  120:2098-2108. 2012
  • Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML..  120:1473-1484. 2012
  • Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining.  119:6187-6197. 2012
  • Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10.  119:6099-6108. 2012
  • Heme-regulated eIF2α kinase activated Atf4 signaling pathway in oxidative stress and erythropoiesis.  119:5276-5284. 2012
  • Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.  119:5294-5300. 2012
  • CD86 is expressed on murine hematopoietic stem cells and denotes lymphopoietic potential.  119:4889-4897. 2012
  • PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential.  119:4953-4962. 2012
  • ADAMTS13 meets MR, then what?.  119:3652-3654. 2012
  • Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.  119:3836-3843. 2012
  • Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group Study.  119:3512-3522. 2012
  • GM-CSFRα: The sex-chromosome link to t(8;21)+ AML?.  119:2976-2977. 2012
  • Negative effects of GM-CSF signaling in a murine model of t(8;21)–induced leukemia.  119:3155-3163. 2012
  • Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.  119:1904-1914. 2012
  • Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: A Children's Oncology Group study.  119:1872-1881. 2012
  • Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.  119:1915-1921. 2012
  • Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.  119:1501-1510. 2012
  • Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.  119:1522-1531. 2012
  • Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.  119:1274-1282. 2012
  • A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32.  119:469-475. 2012
  • ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.  118:6920-6929. 2011
  • The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.  118:6544-6552. 2011
  • FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling.  118:6332-6341. 2011
  • Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.  118:6023-6029. 2011
  • Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia.  118:5914-5917. 2011
  • Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.  118:5565-5572. 2011
  • Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia.  118:4902-4909. 2011
  • Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: A report from the bone marrow transplant survivor study (BMTSS).  118:4723-4731. 2011
  • Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.  118:4258-4264. 2011
  • Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.  118:4188-4198. 2011
  • Follicular lymphoma tumor-infiltrating T-helper (T H) cells have the same polyfunctional potential as normal nodal T H cells despite skewed differentiation.  118:3591-3602. 2011
  • Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.  118:2159-2169. 2011
  • Acritical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.  118:1504-1515. 2011
  • Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: A report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).  118:1413-1420. 2011
  • MiRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.  118:1034-1040. 2011
  • Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.  118:282-288. 2011
  • ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway.  118:156-166. 2011
  • Long-term risk for subsequent leukemia after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study.  117:6315-6318. 2011
  • Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality.  117:6172-6183. 2011
  • Plant homologue constitutive photomorphogenesis 9 (COP9) signalosome subunit CSN5 regulates innate immune responses in macrophages.  117:4796-4804. 2011
  • Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells.  117. 2011
  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.  117:3294-3301. 2011
  • The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.  117:3391-3401. 2011
  • Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.  117:1301-1307. 2011
  • Data quality in the study of the mechanisms of extracorporeal photochemotherapy.  117:366-367. 2011
  • In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.  116:6101-6105. 2010
  • BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  116:5660-5669. 2010
  • Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.  116:4958-4967. 2010
  • Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: Correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.  116:4874-4884. 2010
  • FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  116:3622-3626. 2010
  • Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: A report from the Bone Marrow Transplant Survivor Study.  116:3129-3139. 2010
  • Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: Possible role in 20q - Polycythemia vera.  116:2812-2821. 2010
  • Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: A report from the Children's Oncology Group.  116:1045-1050. 2010
  • Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: A Cancer and leukemia group B study.  116:788-792. 2010
  • Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.  116:71-80. 2010
  • Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.  115:5312-5321. 2010
  • Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins.  115:5057-5060. 2010
  • Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups.  115:3827-3834. 2010
  • Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.  115:2449-2457. 2010
  • Long-term recovery after hematopoietic cell transplantation: Predictors of quality-of-life concerns.  115:2508-2519. 2010
  • Amino acid residues Arg659, Arg660, and Tyr 661 in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.  115:2300-2310. 2010
  • Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.  115:2241-2250. 2010
  • ADAMTS13 testing: Why bother?.  115:1475-1476. 2010
  • Foxp1 is an essential transcriptional regulator for the generation of quiescent naive T cells during thymocyte development..  115:510-518. 2010
  • Participation of the urokinase receptor in neutrophil efferocytosis.  114:860-870. 2009
  • Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.  114:1666-1674. 2009
  • T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.  113:6392-6402. 2009
  • A team player: The disintegrin domain of ADAMTS13.  113:5373-5374. 2009
  • Preclinical transfusion-dependent humanized mouse model of β thalassemia major.  113:4763-4770. 2009
  • Eμ-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-κB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.  114:4158-4168. 2009
  • Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.  113:2172-2180. 2009
  • Balance between Id and E proteins regulates myeloid-versus-lymphoid lineage decisions.  113:1016-1026. 2009
  • RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.  113:883-886. 2009
  • TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements.  113:309-316. 2009
  • Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection.  112:3753-3761. 2008
  • A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration.  112:2353-2359. 2008
  • Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.  112:1993-2003. 2008
  • FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.  112:179-187. 2008
  • Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study.  111:5477-5485. 2008
  • A new "initial" case of transfusion-related acute lung injury.  111:5257-5258. 2008
  • The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph - acute lymphoblastic leukemia cells.  111:5093-5100. 2008
  • Characterization of primitive hematopoietic cells from patients with dyskeratosis congenita.  111:4523-4531. 2008
  • Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: A report from the Children's Oncology Group.  111:3276-3285. 2008
  • Monocyte migration to inflamed skin and lymph nodes is differentially controlled by L-selectin and PSGL-1.  111:3126-3130. 2008
  • Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.  111:2329-2338. 2008
  • CREB is a critical regulator of normal hematopoiesis and leukemogenesis.  111:1182-1192. 2008
  • Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.  111:1584-1593. 2008
  • FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.  111:1567-1574. 2008
  • Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the Bone Marrow Transplant Survivor study.  110:3784-3792. 2007
  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.  110:3540-3546. 2007
  • Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: Implications for optimal dosing.  110:3552-3556. 2007
  • Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.  110:2620-2630. 2007
  • The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow.  110:1887-1894. 2007
  • The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.  110:2041-2048. 2007
  • Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: A report from Children's Oncology Group Study P9201.  110:1105-1111. 2007
  • Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study.  109:5164-5167. 2007
  • Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.  109:5411-5421. 2007
  • Interferon-producing killer dendritic cells (IKDCs) arise via a unique differentiation pathway from primitive c-kitHiCD62L+ lymphoid progenitors.  109:4825-4831. 2007
  • Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host.  109:4336-4342. 2007
  • FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection.  109:3786-3793. 2007
  • Expression of a non-DNA-binding isoform of Helios induces T-cell lymphoma in mice.  109:2190-2197. 2007
  • "Doing the locomotion" with the multistep paradigm.  109:1342-1343. 2007
  • Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: A report from the bone marrow transplantation survivor study.  109:1765-1772. 2007
  • The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.  109:1782-1789. 2007
  • Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).  109:926-935. 2007
  • A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB)..  110:4430-4430. 2007
  • FCRL2 expression is predictive of IgVH mutation status and clinical progression in chronic lymphocytic leukemia.  S110:150a-151a. 2007
  • Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.  109:46-51. 2007
  • Formation ofNitroso compounds in the reaction of nitrite and hemoglobin..  108:449A-449A. 2006
  • Study of black-white differences in anemia prevalence in the United States: The reasons for geographic and racial differences in stroke study..  108:383A-383A. 2006
  • Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: A report from the Bone Marrow Transplant Survivor Study.  108:2867-2873. 2006
  • Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts.  108:2207-2215. 2006
  • Correction of sickle cell disease by homologous recombination in embryonic stem cells.  108:1183-1188. 2006
  • Escaping inhibition by self-mutation.  108:7. 2006
  • Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461.  108:63-73. 2006
  • HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.  107:4781-4789. 2006
  • High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension.  107:3486-3488. 2006
  • A new twist in myeloma treatment.  107:413-414. 2006
  • Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation.  107:566-574. 2006
  • Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: A Children's Cancer Group study.  106:4043-4049. 2005
  • LPS induces CD40 gene expression through the activation of NF-κB and STAT-1α in macrophages and microglia.  106:3114-3122. 2005
  • Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8.  106:1203-1206. 2005
  • Late mortality in survivors of autologous hematopoietic-cell transplantation: Report from the Bone Marrow Transplant Survivor Study.  105:4215-4222. 2005
  • Detection of BCR-ABL kinase mutations in CD34 + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.  105:2093-2098. 2005
  • The nitric oxide pathway modulates hemangioblast activity of adult hematopoietic stem cells.  105:1916-1922. 2005
  • FcRH1: An activation coreceptor on human B cells.  105:1121-1126. 2005
  • Heparanase promotes the spontaneous metastasis of myeloma cells to bone.  105:1303-1309. 2005
  • Association of immune abnormalities with telomere shortening in autosomal-dominant dyskeratosis congenita.  105:682-688. 2005
  • The ETS family transcription factor PU.1 is necessary for the maintenance of fetal liver hematopoietic stem cells.  104:3894-3900. 2004
  • Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: Results from the Bone Marrow Transplant Survivor Study.  104:1898-1906. 2004
  • Transduction of NO-bioactivity by the red blood cell in sepsis: Novel mechanisms of vasodilation during acute inflammatory disease.  104:1375-1382. 2004
  • Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.  104:227-236. 2004
  • Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.  103:4036-4042. 2004
  • Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.  103:4043-4049. 2004
  • Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.  103:4188-4194. 2004
  • Familial eosinophilia: A benign disorder?.  103:4050-4055. 2004
  • BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.  103:3167-3174. 2004
  • Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.  103:2939-2941. 2004
  • Dendritic cell differentiation potential of mouse monocytes: monocytes represent immediate precursors of CD8- and CD8+ splenic dendritic cells.  103:2668-2676. 2004
  • Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study.  103:2822-2826. 2004
  • Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.  103:473-478. 2004
  • Correction of a mouse model of sickle cell disease: Lentiviral/ antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells.  102:4312-4319. 2003
  • Elevated endothelial cAMP reduces cell adhesion molecule expression on and sickle erythrocyte adhesion to TNF-alpha stimulated human dermal microvascular endothelium..  102:82A-82A. 2003
  • Histamine promotes sickle erythrocyte adherence to endothelium under flow through stimulation of H-2 and H-4 via nitric oxide synthase signaling..  102:259A-259A. 2003
  • Novel function of human hemoglobin as a nitrite reductase regulates nitric oxide homeostasis and hypoxic vasodilation..  102:255A-255A. 2003
  • Shear stress modulation of cytokine-induced sickle cell adherence to endothelium..  102:264A-264A. 2003
  • The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans.  102:2916-2924. 2003
  • BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study.  102:1613-1618. 2003
  • Blood flow and SNOHb: an allosteric controversy.  102:412-413. 2003
  • S-nitrosohemoglobin is distinguished from other nitrosovasodilators by unique oxygen-dependent responses that support an allosteric mechanism of action [4] (multiple letters).  102:410-413. 2003
  • Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.  101:4660-4666. 2003
  • Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.  101:4701-4707. 2003
  • Pax5 determines B- versus T-cell fate and does not block early myeloid-lineage development.  101:4342-4346. 2003
  • Vasoactivity of S-nitrosohemoglobin: Role of oxygen, heme, and NO oxidation states.  101:4408-4415. 2003
  • Cellular response to hypoxia involves signaling via Smad proteins.  101:2253-2260. 2003
  • Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study.  101:2015-2023. 2003
  • V(D)J recombinatorial repertoire diversification during intraclonal pro-B to B-cell differentiation.  101:1030-1037. 2003
  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461).  100:4325-4336. 2002
  • Microarray analysis of a t(4;11)q(21;23) cell line with B-lineage developmental potential reveals a distinct pattern of Hox gene.  100:195B-195B. 2002
  • Microcirculatory effects of Poloxamer 188 in transgenic sickle cell mice..  100:664A-664A. 2002
  • Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.  100:3002-3007. 2002
  • gp120-mediated induction of the MAPK cascade is dependent on the activation state of CD4+ lymphocytes.  100:2546-2553. 2002
  • Racial and ethnic differences in survival of children with acute lymphoblastic leukemia.  100:1957-1964. 2002
  • Copper deficiency masquerading as myelodysplastic syndrome.  100:1493-1495. 2002
  • Soluble syndecan-1 promotes growth of myeloma tumors in vivo.  100:610-617. 2002
  • Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia.  100:67-71. 2002
  • Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial.  99:4336-4342. 2002
  • Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983.  99:4257-4264. 2002
  • Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.  99:3792-3800. 2002
  • Moyamoya syndrome in childhood sickle cell disease: A predictive factor for recurrent cerebrovascular events.  99:3144-3150. 2002
  • Sperm protein 17 is not expressed on normal leukocytes [3] (multiple letters).  99:3479-3481. 2002
  • Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia.  99:2617-2619. 2002
  • Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.  99:1745-1757. 2002
  • Differential gene expression profiling of adult murine hematopoietic stem cells.  99:488-498. 2002
  • Pro-B-cell to pre-B-cell development in B-lineage acute lymphoblastic leukemia expressing the MLL/AF4 fusion protein.  98:3398-3405. 2001
  • Transgenic mice expressing exclusively HbS are more susceptible to endotoxin and desmopressin challenge..  98:488A-488A. 2001
  • Slow, programmed maturation of the immunoglobulin HCDR3 repertoire during the third trimester of fetal life.  98:2745-2751. 2001
  • Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion.  98:2160-2165. 2001
  • Dermal and pulmonary inflammatory disease in E-selectin and P-selectin double-null mice is reduced in triple-selectin-null mice.  98:727-735. 2001
  • Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers.  98:505-512. 2001
  • High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection (Cancer and Leukemia Group B Study 8361).  97:3574-3580. 2001
  • Fatal sickle cell crisis after granulocyte colony-stimulating factor administration [1].  97:3313-3314. 2001
  • Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle.  97:2278-2285. 2001
  • A pilot study of anti-cd20 moab mtuximab in patients with refractory immune thrombocytopenic purpura (TTP).  96. 2000
  • Adoptive immunotherapy with allogeneic EBV CTL for organ transplant patients with ebv induced lymphoproliferative disease.  96. 2000
  • Amifostine (ETHOYL) in Combination with topotecan and ARA-C for patients with poor risk myelodysplasia (MDS) and secondary acute myelogenous leukemia.  96. 2000
  • Generation of novel embryonic stem cell lines from knockout-transgenic sickle cell disease mice: a new tool for therapeutic intervention.  96. 2000
  • Moyamoya collaterals are associated with high risk of recurrent cerebrovascular accidents (CVAs) in patients with sickle cell anemia (SCA) on transfusion after a stroke.  96. 2000
  • Oral chlorambucil and prednisone with rituximab as initial chemotherapy for low grade non hodgkin's lymphoma: a phase ii trial.  96. 2000
  • De novo IgH gene segment rearrangement leads to functional pre-BCR expression in a novel B-lineage all cell like expressing MLL/AF4..  96:617A-+. 2000
  • Endogenous Notch-1 cleavage in human B-lineage cells..  96:615A-+. 2000
  • Microcirculatory effects of blocking cell adhesion molecules in transgenic sickle cell mice..  96:528A-528A. 2000
  • High levels of soluble syndecan-1 in myeloma-derived bone marrow: Modulation of hepatocyte growth factor activity.  96:3139-3146. 2000
  • New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group report of 343 cases.  96:2543-2549. 2000
  • Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.  96:2528-2536. 2000
  • Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny.  96:894-901. 2000
  • Molecular modification of a recombinant anti-CD3ε-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model.  96:1157-1165. 2000
  • Hydroxychloroquine inhibits calcium signals in T cells: A new mechanism to explain its immunomodulatory properties.  95:3460-3466. 2000
  • Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors.  95:1588-1593. 2000
  • Fatal graft-versus-host disease associated with solid-organ transplantation.  96. 2000
  • Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821..  94:3707-3716. 1999
  • Notch expression and signaling in normal and leukemic human B-lineage cells..  94:436A-436A. 1999
  • Screening of antisickling agents by the new systematic multi-level analysis protocol developed at the sickle cell disease reference laboratory..  94:199A-199A. 1999
  • Sickle red blood cell (SRBC) adherence to endothelial cells (EC) is regulated by hemodynamics and receptor affinity..  94:675A-675A. 1999
  • Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.  94:3242-3250. 1999
  • Dysregulated myelopoiesis in mice lacking Jak3.  94:932-939. 1999
  • Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia group B experience.  93:3983-3993. 1999
  • Recombinant human thrombopoietin in combination with granulocyte colony- stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.  93:2798-2806. 1999
  • Comparative analysis of autografting in chronic myelogenous leukemia: Effects of priming regimen and marrow or blood origin of stem cells.  92:1820-1831. 1998
  • Rh50 glycoprotein gene and RH(null) disease: A silent splice donor is trans to a Gly279→Glu missense mutation in the conserved transmembrane segment.  92:1776-1784. 1998
  • Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses.  92:1324-1333. 1998
  • Endothelial cells in physiology and in the pathophysiology of vascular disorders.  91:3527-3561. 1998
  • Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.  91:3414-3422. 1998
  • Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation.  91:2679-2688. 1998
  • E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A pediatric oncology group study.  91:1021-1028. 1998
  • Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2.  91:399-405. 1998
  • Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: A Cancer and Leukemia Group B Study.  90:4532-4538. 1997
  • Erythrocyte adhesion to cremaster endotheilum in mice with abnormal hemoglobin is increased by topical endotoxin..  90:1960-1960. 1997
  • Ig D(H) gene segment transcription and rearrangement before surface expression of the pan-B-cell marker CD19 in normal human bone marrow.  90:736-744. 1997
  • Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group study.  89:3960-3966. 1997
  • Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment.  89:3596-3606. 1997
  • Autologous transplantation therapy for chronic myelogenous leukemia.  89:2623-2634. 1997
  • Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and leukemia group B study 9022.  89:780-788. 1997
  • Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras.  88:4611-4619. 1996
  • Phorbol ester stimulation increases sickle erythrocyte adherence to endothelium: A novel pathway involving α4β1 integrin receptors on sickle reticulocytes and fibronectin.  88:4348-4358. 1996
  • Continuous recirculating contact enhances adhesion of sickle red blood cells to endothelial cells..  88:27-27. 1996
  • Inhibition of plasma-mediated sickle erythrocyte adherence to microvascular endothelium by poloxamer compounds..  88:24-24. 1996
  • Sickle red blood cell adherence to vascular endothelium is more tenacious in confined flow channels.  88:23-23. 1996
  • Tenacity of sickle red blood cell (SRBC) endothelial cell (EC) adherence is augmented under hemodynamic shear and by involvement of multiple adhesion pathways..  88:2585-2585. 1996
  • Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin.  88:2973-2979. 1996
  • Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: Immunophenotypic analysis and factors affecting the speed of recovery.  88:1089-1097. 1996
  • BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.  87:4770-4779. 1996
  • Molecular analysis of t(11;19) breakpoints in childhood acute leukemias.  87:4804-4808. 1996
  • Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells.  87:4057-4067. 1996
  • Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia.  87:3883-3891. 1996
  • Malignant neoplasms following bone marrow transplantation.  87:3633-3639. 1996
  • Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARα-mediated increase of type II transglutaminase.  87:1939-1950. 1996
  • Increased tenacity of sickle erythrocyte-endothelial cell adherence by involvement of multiple receptor-ligand interactions.  86:1180-1180. 1995
  • Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages.  85:3636-3645. 1995
  • Heterogeneity in CBFβ/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.  85:3695-3703. 1995
  • CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.  85:2910-2917. 1995
  • Double-stranded RNA induces sickle erythrocyte adherence to endothelium: A potential role for viral infection in vaso-occlusive pain episodes in sickle cell anemia.  85:2945-2950. 1995
  • IN-VITRO COMPARISON OF KNOWN MECHANISMS OF SICKLE ERYTHROCYTE ADHERENCE TO ENDOTHELIUM - BIOPHYSICAL STUDIES TO PREDICT THE RELATIVE IMPORTANCE OF COMPETING ADHERENCE PATHWAYS IN-VIVO.  84:A407-A407. 1994
  • SHORT-TERM CONTACT WITH SICKLE ERYTHROCYTES INHIBITS SHEAR-INDUCED ELONGATION OF ARTERIAL ENDOTHELIUM.  84:A407-A407. 1994
  • SICKLE ERYTHROCYTES STIMULATED WITH PHORBOL ESTER ADHERE TO ENDOTHELIUM VIA ACTIVATED ALPHA-4-BETA-1 INTEGRIN ON SICKLE RETICULOCYTES AND FIBRONECTIN ON ENDOTHELIUM.  84:A408-A408. 1994
  • Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group Study.  84:570-573. 1994
  • The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia.  83:330-335. 1994
  • Childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): An update [4].  83:2384-2385. 1994
  • Further definition of 20q deletion in myeloid leukemia using fluorescence in situ hybridization [1].  84:2821-2823. 1994
  • Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency.  84:859-865. 1994
  • PLASMA ENHANCEMENT OF SICKLE RED-BLOOD-CELL (RBC) ADHERENCE TO MICROVASCULAR ENDOTHELIAL-CELLS (MEC) MEDIATED BY INTEGRIN RECEPTORS CAN BE INHIBITED BY CONFORMATIONALLY CONSTRAINED RGD PEPTIDES.  82:A353-A353. 1993
  • SICKLE RED-BLOOD-CELLS (RBC) INDUCE EXPRESSION OF CELL-ADHESION MOLECULES ON HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS (HUVEC).  82:A352-A352. 1993
  • STIMULATION OF SICKLE ERYTHROCYTES WITH PHORBOL ESTER PROMOTES ADHERENCE TO ENDOTHELIUM - A POTENTIAL ROLE FOR ACTIVATED VLA-4 (ALPHA-4-BETA-1) ON SICKLE RETICULOCYTES.  82:A352-A352. 1993
  • SYNTHETIC DOUBLE-STRANDED-RNA INCREASES ADHERENCE OF SICKLE RED-BLOOD-CELLS (SRBC) TO HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS (HUVEC) VIA ALPHA-4-BETA-1 - VASCULAR CELL-ADHESION MOLECULE-1 (VCAM-1) PATHWAY.  82:A352-A352. 1993
  • An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation.  81:2860-2865. 1993
  • Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: A Pediatric Oncology Group study.  81:2110-2117. 1993
  • Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.  81:767-774. 1993
  • HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.  81:3197-3203. 1993
  • Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency.  81:3052-3059. 1993
  • Identification and characterization of a high-affinity granulocyte- macrophage colony-stimulating factor receptor on primary rat oligodendrocytes.  82:3279-3282. 1993
  • Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: Implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: A Pediatric Oncology Group study.  82:1086-1091. 1993
  • Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion.  81:2137-2143. 1993
  • Trisomy 21 in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group Study (8602).  82:3098-3102. 1993
  • α4β1-Integrin expression on sickle reticulocytes: Vascular cell adhesion molecule-1-dependent binding to endothelium.  82:1891-1899. 1993
  • Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group study.  80:1316-1323. 1992
  • Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia.  79:1781-1788. 1992
  • G19.4(αCD3) x B43(αCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.  80:2826-2834. 1992
  • Isochromosomes in childhood acute lymphoblastic leukemia: A collaborative study of 83 cases.  79:2384-2391. 1992
  • Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B- progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: A Pediatric Oncology Group Study.  79:3316-3324. 1992
  • A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14).  78:2996-3003. 1991
  • Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): A collaborative study of 40 cases.  77:440-447. 1991
  • Consistent involvement of the BCR gene by 9;22 breakpoints in pediatric acute leukemias.  77:324-330. 1991
  • Intravenous Anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect.  77:1884-1893. 1991
  • Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study.  77:1050-1056. 1991
  • The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias.  77:687-693. 1991
  • The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: A pediatric oncology group study.  78:748-752. 1991
  • Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid < 45 line.  75:1170-1177. 1990
  • Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood.  76:590-596. 1990
  • Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study.  76:489-494. 1990
  • Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19) (q23;p13): A pediatric oncology group study.  76:117-122. 1990
  • Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection.  76:463-472. 1990
  • The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study.  76:1220-1224. 1990
  • Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia.  73:662-665. 1989
  • High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance.  74:326-333. 1989
  • Monocyte-platelet interaction in immune and nonimmune thrombocytopenia.  74:1328-1331. 1989
  • Bone marrow origin of a B-cell lymphoma.  72:94-101. 1988
  • Analysis with antiidiotype antibody of a patient with chronic lymphocytic leukemia and a large cell lymphoma (Richter's syndrome).  70:45-50. 1987
  • Lack of association between abnormalities of the chromosome 9 short arm and either 'lymphomatous' features or T cell phenotype in childhood acute lymphocytic leukemia.  69:735-738. 1987
  • Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia.  69:278-283. 1987
  • tdic(9;12): A nonrandom chromosome abnormality in childhood B-cell precursor acute lymphoblastic leukemia: A pediatric oncology group study.  70:1962-1965. 1987
  • Diffuse large cell lymphoma in a patient with hairy cell leukemia: Immunoglobulin gene analysis reveals separate clonal origins.  67:739-744. 1986
  • Sl/Sl(d) mouse bone marrow stroma in vitro contains an active radiation-sensitive inhibitor of normal hemopoiesis.  68:1201-1206. 1986
  • Acute leukemias associated with the 4;11 chromosome translocation have rearranged immunoglobulin heavy chain genes.  66:33-38. 1985
  • Localization of thrombospondin in clots formed in situ.  66:1098-1104. 1985
  • Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.  63:639-648. 1984
  • Pre-B cell leukemia associated with chromosome translocation 1;19.  63:721-724. 1984
  • Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura.  62:480-486. 1983
  • Malignant lymphoma, mixed cell type, diffuse.  62:200-208. 1983
  • Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies.  61:830-837. 1983
  • Human blood monocytes and platelets share a cell surface component.  60:767-771. 1982
  • An analysis of clinical and laboratory features of acute lymphocytic leukemias with emphasis on 35 children with pre-B leukemia.  58:135-140. 1981
  • A new glucose-6-phosphate dehydrogenase deficient variant in a patient with Chediak-Higashi syndrome.  56:476-480. 1980
  • Wiskott-Aldrich syndrome: Cellular impairments and their implication for carrier detection.  56:1048-1054. 1980
  • Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.  54:824-836. 1979
  • International Standard Serial Number (issn)

  • 0006-4971
  • Electronic International Standard Serial Number (eissn)

  • 0006-4971
  • 1528-0020